Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa; Veterinary Population Management Laboratory, Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Department of Production Animal Studies, Faculty of Veterinary Science, University of Pretoria, Onderstepoort, South Africa.
Vaccine. 2019 Feb 28;37(10):1299-1306. doi: 10.1016/j.vaccine.2019.01.053. Epub 2019 Feb 4.
Commercial and regulatory limitations associated with native porcine zona pellucida (pZP) vaccines formulated with Freund's adjuvants may be overcome by developing effective recombinant ZP vaccines (reZP) and identifying alternative adjuvant formulations. A two-part preparatory study used 15 geldings and identified potentially effective alternative adjuvant formulations based on anti-pZP antibody response following treatment with pZP formulated with Addavax (AddaVax ™, Invivogen), Quil A (Quil-A® Adjuvant, Invivogen), Quil A and Poly (I:C) (HMW VacciGrade™, Invivogen), Pet Gel A (Montanide™ Pet Gel A, Seppic) and Pet Gel A and Poly (I:C). Injection site reactions, rectal temperature and respiratory and heart rates were also monitored for three days post-treatment. Suitable anti-pZP antibody titres were seen in response to Pet Gel A and Pet Gel A and Poly (I:C). Subsequently in 31 mares, following administration of pZP, reZP and a combination of pZP and reZP proteins prepared in Pet Gel A and Poly (I:C), both serum anti-pZP and -reZP antibody responses were monitored. In addition, safety was assessed for up to seven days post-treatment by inspection and palpation of gluteal intramuscular injection sites and measurement of rectal temperature. The measured antibody titres in all treatment groups differed significantly to an adjuvant control group (P < 0.001). Temporal changes in both anti-pZP and -reZP antibody titres in all ZP treatment groups were similar to patterns reported previously in various species vaccinated with pZP formulated with Freund's adjuvants. There were no differences in anti-pZP antibody titres between the pZP and reZP treated groups (P > 0.05). Side effects were mild and transient in nature. This represents the first application of a reZP vaccine formulated with non-Freund's adjuvants evoking a similar antibody titre response to native pZP vaccination in mares.
与含有福氏佐剂的天然猪透明带（pZP）疫苗相关的商业和监管限制，可以通过开发有效的重组 ZP 疫苗（reZP）和确定替代佐剂配方来克服。一项两部分的预备研究使用了 15 匹种马，并根据用 Addavax（AddaVax ™，Invivogen）、Quil A（Quil-A ® 佐剂，Invivogen）、Quil A 和 Poly（I:C）（HMW VacciGrade ™，Invivogen）、Pet Gel A（Montanide ™ Pet Gel A，Seppic）和 Pet Gel A 和 Poly（I:C）配制的 pZP 处理后的抗 pZP 抗体反应，确定了潜在有效的替代佐剂配方。还监测了治疗后三天的注射部位反应、直肠温度以及呼吸和心率。在对 Pet Gel A 和 Pet Gel A 和 Poly（I:C）的反应中观察到了合适的抗 pZP 抗体滴度。随后，在 31 匹母马中，在给予 pZP、reZP 和在 Pet Gel A 和 Poly（I:C）中制备的 pZP 和 reZP 蛋白的组合后，监测了血清抗 pZP 和 -reZP 抗体反应。此外，通过检查和触诊臀肌内注射部位以及测量直肠温度，在治疗后长达七天内评估安全性。所有治疗组的测量抗体滴度与佐剂对照组有显著差异（P<0.001）。所有 ZP 治疗组的抗 pZP 和 -reZP 抗体滴度的时间变化与以前用含有福氏佐剂的 pZP 疫苗接种的各种物种报告的模式相似。pZP 和 reZP 处理组之间的抗 pZP 抗体滴度没有差异（P>0.05）。副作用是轻微和短暂的。这是首次应用不含福氏佐剂的 reZP 疫苗，在母马中引起与天然 pZP 接种相似的抗体滴度反应。
